IntelGenx Technologies Corp. (IGXT)
OTCMKTS: IGXT · Delayed Price · USD
0.164
-0.003 (-1.61%)
Apr 26, 2024, 3:04 PM EDT - Market closed
IntelGenx Technologies Revenue
In the year 2023, IntelGenx Technologies had annual revenue of $1.04M with 9.37% growth. Revenue in the quarter ending December 31, 2023 was $426.00K with 146.24% year-over-year growth.
Revenue (ttm)
$1.04M
Revenue Growth
+9.37%
P/S Ratio
27.56
Revenue / Employee
$21,646
Employees
48
Market Cap
28.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.04M | 89.00K | 9.37% |
Dec 31, 2022 | 950.00K | -585.00K | -38.11% |
Dec 31, 2021 | 1.54M | -9.00K | -0.58% |
Dec 31, 2020 | 1.54M | 802.00K | 108.09% |
Dec 31, 2019 | 742.00K | -1.08M | -59.32% |
Dec 31, 2018 | 1.82M | -3.37M | -64.89% |
Dec 31, 2017 | 5.20M | -25.00K | -0.48% |
Dec 31, 2016 | 5.22M | 125.00K | 2.45% |
Dec 31, 2015 | 5.10M | 3.44M | 207.11% |
Dec 31, 2014 | 1.66M | 711.00K | 75.00% |
Dec 31, 2013 | 948.00K | -260.00K | -21.52% |
Dec 31, 2012 | 1.21M | 768.00K | 174.55% |
Dec 31, 2011 | 440.00K | -897.00K | -67.09% |
Dec 31, 2010 | 1.34M | 58.30K | 4.56% |
Dec 31, 2009 | 1.28M | 302.09K | 30.93% |
Dec 31, 2008 | 976.61K | 141.20K | 16.90% |
Dec 31, 2007 | 835.42K | 569.51K | 214.18% |
Dec 31, 2006 | 265.90K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
IGXT News
- 19 days ago - IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial - GlobeNewsWire
- 22 days ago - IntelGenx Updates Status of Buprenorphine Buccal Film ANDA - GlobeNewsWire
- 5 weeks ago - IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 6 weeks ago - IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow - GlobeNewsWire
- 6 weeks ago - IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences - GlobeNewsWire
- 2 months ago - UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering - GlobeNewsWire
- 2 months ago - IntelGenx Launches Preferred Share Regulation A Offering - GlobeNewsWire
- 4 months ago - IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm® - GlobeNewsWire